Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy
Markus Hoffmann, Anzhalika Sidarovich, Prerna Arora, Nadine Krüger, Inga Nehlmeier, Amy Kempf, Luise Graichen, Martin Sebastian Winkler, Daniela Niemeyer, Christine Goffinet, Christian Drosten, Sebastian Schulz, Hans‐Martin Jäck, Stefan Pöhlmann
Abstract
The interaction of the SARS-CoV-2 spike protein (S) with the cellular receptor ACE2 is considered essential for infection and constitutes the key target for antibodies induced upon infection and vaccination. Here, using a surrogate system for viral entry, we provide evidence that a naturally occurring mutation can liberate SARS-CoV-2 from ACE2-dependence and that ACE2-independent entry may protect the virus from neutralization by an antibody used for COVID-19 therapy.
Topics & Concepts
NeutralizationCoronavirus disease 2019 (COVID-19)VirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakAntibodyPandemicCoronavirus InfectionsImmunologyMedicineInfectious disease (medical specialty)DiseaseOutbreakPathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19